News

Treatment with the investigational therapy STK-001 led to significant reductions in seizure frequency and clinically meaningful improvements in cognition and behavior for children and adolescents with Dravet syndrome, according to data from Phase 1/2 studies and their open-label extensions (OLEs). Developer Stoke Therapeutics said that the findings…

Recurrent seizures in a man with Dravet syndrome and high body temperature were managed by treating the recurrent infections and switching from Zonegran (zonisamide) to Fycompa (perampanel), a case study reports. The researchers recommended that clinicians consider treating infections early and discontinuing Zonegra if the medication causes…

Fycompa (perampanel) was found to safely reduce seizure frequency among patients with genetic forms of epilepsy, including Dravet syndrome, in a recent analysis of real-world treatment data. Findings from the analysis of pooled clinical practice data showed treatment responses among these genetic epilepsy patients were at least as…

Levodopa, the standard treatment for motor symptoms associated with Parkinson’s disease, improved walking abilities in people with Dravet syndrome, according to a small clinical trial. Most walking gains occurred in younger patients with better walking abilities before levodopa treatment. “Our findings suggest that levodopa treatment may be…

A molecule designed to enhance activity at certain GABA-A receptor proteins in the brain protected against seizures and eased anxiety in a mouse model of Dravet syndrome, recent research showed. At higher doses, the medication led to sedative side effects, which scientists believe can be avoided by making sure…

Behavioral development in children and teens with Dravet syndrome generally held stable in the first year of an observational study, though some showed small improvements in communication, according to researchers. Participants in the study, dubbed BUTTERFLY, continued to perform below what would be expected of their typically developing peers…

Encoded Therapeutics has been cleared by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to begin clinical testing of ETX101, an investigational one-time gene therapy for children with Dravet syndrome. A Phase 1/2 clinical study dubbed EXPEDITION will test how safe ETX101 is and how well it…

The National Institute of Drug and Food Surveillance (INVIMA) of Colombia has approved Trunerox as an add-on treatment for seizures in people with Dravet syndrome and Lennox-Gastaut syndrome (LGS). Trunerox, which was developed by the Canadian biopharmaceutical Avicanna, is a proprietary oral formulation of 10% cannabidiol…

Encoded Therapeutics has received clearance from U.S. and Australian regulatory agencies to launch Phase 1/2 clinical trials testing ETX101, its Dravet syndrome gene therapy candidate, in infants and young children with the seizure disorder. In the U.S., the company plans to begin ENDEAVOR (NCT05419492), which will be…

International Epilepsy Day for 2024 aims to promote public understanding of a condition thought to affect some 65 million people globally — including those with Dravet syndrome — to gather support for a 10-year World Health Organization (WHO) epilepsy roadmap. Held annually on the second Monday in February —…